- Home
- SAP vs GILD Comparison
SAP vs GILD Comparison
Compare SAP & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SAP | GILD |
|---|---|---|
| Founded | 1972 | 1987 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.4B | 154.7B |
| IPO Year | 1998 | 1992 |
Fundamental Metrics
Financial Performance| Metric | SAP | GILD |
|---|---|---|
| Price | $249.06 | $122.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 21 |
| Target Price | ★ $340.75 | $128.67 |
| AVG Volume (30 Days) | 1.2M | ★ 6.3M |
| Earning Date | 01-27-2026 | 02-10-2026 |
| Dividend Yield | 0.77% | ★ 2.61% |
| EPS Growth | 159.50 | ★ 6514.05 |
| EPS | ★ 7.07 | 6.42 |
| Revenue | ★ $42,818,256,487.00 | $29,087,000,000.00 |
| Revenue This Year | $9.60 | $3.63 |
| Revenue Next Year | $10.48 | $3.10 |
| P/E Ratio | $34.95 | ★ $18.85 |
| Revenue Growth | ★ 9.70 | 2.79 |
| 52 Week Low | $233.51 | $88.57 |
| 52 Week High | $313.28 | $128.70 |
Technical Indicators
Market Signals| Indicator | SAP | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 56.92 | 50.23 |
| Support Level | $240.19 | $119.33 |
| Resistance Level | $245.15 | $125.11 |
| Average True Range (ATR) | 3.20 | 2.70 |
| MACD | 0.72 | -0.15 |
| Stochastic Oscillator | 96.20 | 53.85 |
Price Performance
Historical ComparisonAbout SAP SAP SE ADS
Founded in Germany in 1972 by former IBM employees, SAP is the world's largest provider of enterprise application software. Known as the leader in enterprise resource planning software, SAP's portfolio also includes software for supply chain management, procurement, travel and expense management, and customer relationship management, among others. The company operates in more than 180 countries and has more than 400,000 customers, approximately 80% of which are small to medium-size enterprises.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).